JBI-1044 / Jubilant Pharmova - LARVOL DELTA

Chronic alcohol consumption promotes pancreatic cancer liver metastasis in mice through PAD4-mediated pre-metastatic niche formation (AACR 2025) - "By regulating neutrophil activity and collagen deposition, PAD4 contributes to the progression of liver metastases. Selective inhibition of PAD4 with JBI-1044 represents a promising therapeutic strategy for managing PDAC liver metastasis in the context of ALD."

Metastases • Preclinical • Liver Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • VIM

A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014-present). (PubMed, Expert Opin Ther Pat) - "Despite PAD4's clear involvement in multiple disease pathways, its detailed mechanism remains insufficiently understood. Selective and potent compounds with improved PK properties have been provided but most research on PAD4 is still at the experimental stage or preclinical development; the most promising is JBI-1044, at the IND stage, while some companies have turned to antibodies despite considerable previous investment in small molecules."

Journal • Review • Cardiovascular • CNS Disorders • Immunology • Oncology

SELECTIVE PAD4 INHIBITION DELAYS METASTATIC TUMOR GROWTH IN THE LIVER BY MODULATING THE HEPATIC TUMOR MICROENVIRONMENT (AASLD 2023) - "PAD4 expression is associated with the progression of PDAC and CRC liver metastasis. PAD4 plays pivotal roles in reshaping liver tumor microenvironment through the modulation of neutrophil functions and collagen deposition. PAD4 inhibition by JBI-1044 suppressed liver metastasis, providing new insight of potential therapies targeting PAD4 in PDAC and CRC liver metastasis."

Biomarker • Metastases • Tumor microenvironment • Colorectal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Liver Failure • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Jubilant Therapeutics Inc. to Present Data on Isoform Selective PAD4 inhibitors in the Treatment of Cancer at the American Association of Cancer Research Annual (AACR) Meeting 2022 (PRNewswire) - "Jubilant Therapeutics Inc...announced...that it will present data on inhibitors of peptidyl arginine deiminase type-4 (PAD4), a potential therapeutic target to treat cancer and autoimmune diseases. The meeting will be held at the American Association of Cancer Research Annual (AACR) in New Orleans between April 8 to 13, 2022, both in person and virtually."

Preclinical • Oncology